01—Abstract
Summary
Summary of the 10-K filed February 6, 2012. Cited figures are marked; the original filing is the authoritative source.
Intuitive Surgical, Inc. (ISRG) reported strong financial performance in its 2011 10-K filing, showcasing continued growth driven by the adoption of its da Vinci Surgical Systems.
The company experienced a significant increase in total revenue, up 24% to $1.76 billiona, propelled by both system sales and a robust increase in recurring revenue from instruments, accessories, and services. The installed base of da Vinci Surgical Systems grew to 2,132 units, supporting approximately 360,000 procedures performed globally during the year. The company highlights the strategic importance of recurring revenue, which represented 56% of total revenue in 2011, indicating a strong and growing installed base utilization.
Key growth drivers included da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP) procedures, alongside an increasing contribution from other surgical specialties like gynecology, cardiothoracic, and general surgery. Intuitive Surgical continues to invest heavily in research and development, focusing on product enhancements and new applications to further drive the adoption of minimally invasive surgery. Looking ahead, the company faces competitive pressures and the inherent risks associated with a novel technology, including market acceptance, regulatory hurdles, and potential economic downturns impacting capital expenditures.
However, its expanding installed base, increasing procedure volumes, and focus on recurring revenue streams position it for continued growth. Investors should monitor the company's ability to maintain its technological leadership, navigate regulatory landscapes, and capitalize on the expanding adoption of robotic-assisted surgery across various medical specialties.
02—Key points
Key Highlights
- Total revenue increased 24% to $1.76 billion in 2011, driven by a 29% increase in da Vinci procedures performed globally.
- Recurring revenue (instruments, accessories, and services) grew 30% to $979.5 million, constituting 56% of total revenue, indicating strong installed base utilization.
- The company sold 534 da Vinci Surgical Systems, an 18% increase from the previous year, expanding its installed base to 2,132 systems worldwide.
- Key procedures like da Vinci Hysterectomy (dVH) and da Vinci Prostatectomy (dVP) continue to be primary growth drivers, with other specialties showing increasing adoption.
- Research and development expenses increased 21% to $140.2 million, reflecting continued investment in product innovation and new applications.
- The company ended the year with substantial liquidity, holding $2.17 billion in cash, cash equivalents, and investments.
- Intuitive Surgical is actively repurchasing shares, with $568.2 million remaining under its authorized stock repurchase program as of December 31, 2011.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Intuitive Surgical kept $0.28.
- Revenue$1.76B100.0%
- Cost of revenue−$483.5M27.5%
- Gross profit$1.27B72.5%
- Operating costs−$579.0M32.9%
- Operating income$694.8M39.5%
- Interest, other & tax−$199.7M11.4%
- Net income$495.1M28.2%
Where FY2011 revenue went
$1.76B- Net income: $495.1M, 28% of revenue
- Cost of revenue: $483.5M, 28% of revenue
- SG&A: $438.8M, 25% of revenue
- R&D: $140.2M, 8.0% of revenue
- Interest, other & tax: $199.7M, 11% of revenue
Kept 28% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 6, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $1.76B$1.41B | +24.4% |
| Cost of Revenue | $483.50M$383.00M | +26.2% |
| Gross Profit | $1.27B$1.03B | +23.7% |
| R&D Expenses | $140.20M$116.00M | +20.9% |
| SG&A Expenses | $438.80M$358.80M | +22.3% |
| Operating Expenses | $579.00M$474.80M | +21.9% |
| Operating Income | $694.80M$555.20M | +25.1% |
| Net Income | $495.10M$381.80M | +29.7% |
| EPS (Basic) | $1.40$1.08 | +29.7% |
| EPS (Diluted) | $1.37$1.05 | +30.1% |
| Shares Outstanding (Basic) | 352.80M352.80M | 0.0% |
| Shares Outstanding (Diluted) | 361.80M362.70M | −0.2% |
05—Questions
Frequently Asked Questions
What is the primary driver of Intuitive Surgical's revenue growth?
Intuitive Surgical's revenue growth is primarily driven by the increasing adoption of its da Vinci Surgical Systems, leading to higher sales of the systems themselves, as well as a significant increase in recurring revenue from instruments, accessories, and service contracts used with the installed systems. The growing number of procedures performed globally is a key indicator of this growth.
How diversified is Intuitive Surgical's revenue by product type?
In 2011, revenue was diversified between product sales (systems, instruments, and accessories) and service revenue. Product revenue accounted for approximately 84% of total revenue ($1.48 billion), while service revenue represented 16% ($278.4 million). The company aims for recurring revenue (instruments, accessories, and services) to become a larger percentage of total revenue in the future.
What are the main surgical specialties where the da Vinci system is being adopted?
Intuitive Surgical's da Vinci system is primarily adopted in urologic surgery, gynecologic surgery, general surgery, cardiothoracic surgery, and head and neck surgery. Urologic procedures like prostatectomy and partial nephrectomy, and gynecologic procedures like hysterectomy, myomectomy, and sacral colpopexy are key areas of focus and adoption.
What are the key risks highlighted in the filing for investors to consider?
Key risks include the need for continued market acceptance of da Vinci surgery, competition from existing and emerging technologies, potential delays or failures in new product introductions, long and variable capital sales cycles, seasonality in business, risks associated with international operations, reliance on sole/single source suppliers, and the impact of healthcare policy changes and reimbursement uncertainties. Product liability claims and intellectual property protection are also noted risks.
06—Continue